Ishibashi Katsuhiko, Iwai Hiroki, Koga Hisashi
Department of Orthopaedic Surgery, Iwai Orthopaedic Medical Hospital, Tokyo, Japan.
Department of Orthopaedic Surgery, Inanami Spine and Joint Hospital, Tokyo, Japan.
J Spine Surg. 2019 Jun;5(Suppl 1):S115-S121. doi: 10.21037/jss.2019.04.24.
Chemonucleolysis is a minimally invasive treatment for cervical and lumbar intervertebral disc herniation (IDH). While this procedure has existed for more than 50 years, it has yet to become an established practice. The main reason for this is the low specificity of enzymes targeting nucleus pulposus (NP). Although two enzymes (chymopapain and collagenase) have been used in clinical settings, severe adverse events have discouraged widespread use. The recently introduced enzyme chondroitin sulfate ABC endolyase may allow a new era of chemonucleolysis because of its high specificity for NP.
化学髓核溶解术是一种用于治疗颈椎和腰椎椎间盘突出症(IDH)的微创治疗方法。虽然该手术已经存在了50多年,但尚未成为一种既定的治疗方法。主要原因是靶向髓核(NP)的酶的特异性较低。尽管两种酶(木瓜凝乳蛋白酶和胶原酶)已用于临床,但严重的不良事件阻碍了其广泛应用。最近引入的酶硫酸软骨素ABC内切酶可能会开启化学髓核溶解术的新时代,因为它对NP具有高特异性。